Primary: Serum levels of asymmetrical dimethylarginine (endothelial dysfunction) and hs-CRP (inflammation); Secondary: IL-6, TNF-α, BP reduction, safety parameters (e.g., hyperkalemia). This evidence concerns the gene TNF and endothelial dysfunction.